Efficacy and Safety of Pemigatinib in Participants With Solid Tumors With FGFR Mutations or Translocations (FIGHT-208)
Public ClinicalTrials.gov record NCT04003623. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumors Harboring Activating FGFR Mutations or Translocations (FIGHT-208)
Study identification
- NCT ID
- NCT04003623
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Incyte Corporation
- Industry
- Enrollment
- 1 participant
Conditions and interventions
Interventions
- Pemigatinib Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 30, 2019
- Primary completion
- Jun 11, 2020
- Completion
- Jun 11, 2020
- Last update posted
- May 9, 2022
2019 – 2020
United States locations
- U.S. sites
- 11
- U.S. states
- 10
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Compassionate Cancer Care Medical Group | Fountain Valley | California | 92708 | — |
| Ocala Oncology Center | Ocala | Florida | 34474 | — |
| Hawaii Cancer Care | Honolulu | Hawaii | 96813 | — |
| Illinois Cancer Care | Peoria | Illinois | 61615 | — |
| FMH James M Stockman Cancer Institute | Frederick | Maryland | 21702 | — |
| New Jersey Cancer Care and Blood Disorders | Belleville | New Jersey | 07109 | — |
| TriHealth | Cincinnati | Ohio | 45220 | — |
| Sanford Cancer Center | Sioux Falls | South Dakota | 51704 | — |
| Mary Crowley Cancer Center | Dallas | Texas | 75230 | — |
| Oncology Consultants | Houston | Texas | 77030 | — |
| Utah Cancer Specialists | Salt Lake City | Utah | 84106 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04003623, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 9, 2022 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04003623 live on ClinicalTrials.gov.